Research Policy
Based on the long history and know-how in treatment and medicine field, the JW Holdings constantly researching and developing innovative new medicine.
We are targeting the diseases with high demand for medical unmet needs, concentrating on the development of innovative
new medicines using the JW’s unique technology, and conducting research activities in line with global trends through open innovation.
We are targeting the diseases with high demand for medical unmet needs, concentrating on the development of innovative
new medicines using the JW’s unique technology, and conducting research activities in line with global trends through open innovation.
Main interesting field
- Cancer stem cell
- Regenerative medicine
- Immunotonics
foundation technique
- JWELRY/HTS
- DC remedy /CTP Technology
- Structure-based coupling Compound smear method
Open innovation
- Medical information Big Data
- Biomarker
- Clinical brokerage
The JW Shinyak has been focusing on the development of innovative new medicines with its key technologies as cancer stem cells,
regenerative medicine, and immune cancer medicines based on our long-established base technology.
regenerative medicine, and immune cancer medicines based on our long-established base technology.
Target indication
-
Immunotonics
- Increased seepage of immune cells in tumor micro environments
- Effect of combined treatment with targeted treatment agents
-
Cancer stem cell
- Survival, multiplication, and transition of tumor cells
- Omnipotentiality and differentiation of cancer stem cells
-
Regenerative medicine
- Rise and Play of Various Organizations
- Growth and differentiation of stem cells